Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cogent Biosciences (COGT) Non Operating Income (2017 - 2026)

Cogent Biosciences' Non Operating Income history spans 10 years, with the latest figure at -$140000.0 for Q1 2026.

  • Quarterly Non Operating Income fell 104.75% to -$140000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$155000.0 through Mar 2026, down 100.82% year-over-year, with the annual reading at -$20000.0 for FY2025, 100.1% down from the prior year.
  • Non Operating Income came in at -$140000.0 for Q1 2026, down from -$6000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $5.8 million in Q4 2024 to a low of -$10.9 million in Q4 2023.
  • The 5-year median for Non Operating Income is $784000.0 (2022), against an average of $1.1 million.
  • Year-over-year, Non Operating Income crashed 793.13% in 2023 and then skyrocketed 294800.0% in 2025.
  • Cogent Biosciences' Non Operating Income stood at -$1.2 million in 2022, then tumbled by 793.13% to -$10.9 million in 2023, then skyrocketed by 153.21% to $5.8 million in 2024, then plummeted by 100.1% to -$6000.0 in 2025, then plummeted by 2233.33% to -$140000.0 in 2026.
  • Per Business Quant, the three most recent readings for COGT's Non Operating Income are -$140000.0 (Q1 2026), -$6000.0 (Q4 2025), and -$3000.0 (Q3 2025).